Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Change in Accured Expenses came in at $4.7 million in Q1 2026, up 236.76% year-on-year from $1.4 million in Q1 2025, and up 145.48% quarter-over-quarter from -$10.3 million in Q4 2025.
Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 236.76% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 170.27% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, down 19.31% from the prior year.
- Change in Accured Expenses grew to $4.7 million in Q1 2026 per SRRK's latest filing, from -$10.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $16.4 million in Q2 2025 and bottomed at -$10.3 million in Q4 2025.
- The 5-year median for Change in Accured Expenses is $1.6 million (2022), against an average of $1.6 million.
- Biggest YoY gain for Change in Accured Expenses was 3230.83% in 2025; the steepest drop was 663.35% in 2025.
- Year by year, Change in Accured Expenses stood at $1.6 million in 2022, then soared by 91.26% to $3.0 million in 2023, then plunged by 39.01% to $1.8 million in 2024, then tumbled by 663.35% to -$10.3 million in 2025, then surged by 145.48% to $4.7 million in 2026.
- Per Business Quant, the three latest SRRK Change in Accured Expenses figures stand at $4.7 million (Q1 2026), -$10.3 million (Q4 2025), and $5.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Scholar Rock Holding | 6.28 Bn | 6.28 Bn | - | 4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.68 Mn |
| Mar 31, 2026 | 4.68 Mn |
| Dec 31, 2025 | -10.30 Mn |
| Dec 31, 2025 | -10.30 Mn |
| Sep 30, 2025 | 5.80 Mn |
| Sep 30, 2025 | 5.80 Mn |
| Jun 30, 2025 | 16.42 Mn |
| Jun 30, 2025 | 16.42 Mn |
| Mar 31, 2025 | -3.43 Mn |
| Mar 31, 2025 | -3.43 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | 7.25 Mn |
| Sep 30, 2024 | 7.25 Mn |
| Jun 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 493,000.00 |
| Mar 31, 2024 | 963,000.00 |
| Mar 31, 2024 | 963,000.00 |
| Dec 31, 2023 | 3.00 Mn |
| Dec 31, 2023 | 3.00 Mn |